Key Takeaways
- • Arey, a Los Angeles-based hair-care brand targeting graying hair, closed a Series A funding round led by Unilever Ventures with participation from existing investors Greycroft and Female Founders Fund.
- • Series A capital will fund new product development, clinical research, retail expansion, and hiring across the organization.
- • The funding announcement precedes the publication of Arey's first clinical trial results in November 2026, which demonstrated that most trial participants experienced fewer or no new gray hairs.
- • Unilever Ventures' lead investment signals strategic interest from a major consumer goods conglomerate in the specialized hair-care segment, particularly in claims-backed solutions for age-related hair concerns.
Summary
Arey, a Los Angeles-based hair-care company specializing in graying hair solutions, has secured Series A funding led by Unilever Ventures. The round included continued participation from the brand's existing backers, Greycroft and Female Founders Fund, underscoring investor confidence in the company's market position and growth trajectory.
The capital infusion will be deployed across four strategic priorities: new product development, clinical research initiatives, retail expansion, and workforce expansion. This diversified allocation suggests Arey intends to deepen its scientific credibility while simultaneously scaling distribution and operational capacity.
The timing of this funding announcement is strategically significant, coinciding with the forthcoming publication of Arey's inaugural clinical trial in November 2026. According to preliminary findings, a substantial majority of trial participants observed either fewer new gray hairs or no new gray hair growth, providing third-party validation for the brand's core product claims. This clinical evidence, combined with backing from Unilever Ventures—the corporate venture arm of consumer goods giant Unilever—positions Arey within the emerging category of clinically validated, science-backed hair-care solutions targeting demographic and age-related concerns.
Unilever Ventures' leadership of this round represents a notable endorsement of the graying hair treatment market and suggests the conglomerate views specialized hair-care as a growth category worthy of venture-scale investment, potentially signaling broader corporate appetite for emerging brands in the personal care space.
The capital infusion will be deployed across four strategic priorities: new product development, clinical research initiatives, retail expansion, and workforce expansion. This diversified allocation suggests Arey intends to deepen its scientific credibility while simultaneously scaling distribution and operational capacity.
The timing of this funding announcement is strategically significant, coinciding with the forthcoming publication of Arey's inaugural clinical trial in November 2026. According to preliminary findings, a substantial majority of trial participants observed either fewer new gray hairs or no new gray hair growth, providing third-party validation for the brand's core product claims. This clinical evidence, combined with backing from Unilever Ventures—the corporate venture arm of consumer goods giant Unilever—positions Arey within the emerging category of clinically validated, science-backed hair-care solutions targeting demographic and age-related concerns.
Unilever Ventures' leadership of this round represents a notable endorsement of the graying hair treatment market and suggests the conglomerate views specialized hair-care as a growth category worthy of venture-scale investment, potentially signaling broader corporate appetite for emerging brands in the personal care space.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.